DAZAP1 Antibody
Description
Introduction to DAZAP1 Antibody
The DAZAP1 antibody is a research-grade immunoglobulin designed to detect the DAZ-associated protein 1 (DAZAP1), an RNA-binding protein implicated in splicing regulation, cell proliferation, and cancer progression. Commercially available antibodies, such as those from Proteintech (catalog #11120-1-AP) and Abcam (catalog #ab237519), are validated for use in immunohistochemistry (IHC), western blotting (WB), and immunofluorescence (ICC/IF) applications . These reagents enable researchers to study DAZAP1’s subcellular localization and expression in diverse tissues, including cancerous specimens .
Applications in Research
DAZAP1 antibodies are critical tools in studying the protein’s roles in:
-
Alternative splicing: DAZAP1 regulates splicing events via interactions with hnRNP A1 and the MEK/Erk pathway . Antibodies enable visualization of its nuclear/cytoplasmic translocation .
-
Cancer biology: Elevated DAZAP1 expression correlates with poor prognosis in pancreatic cancer (PC) and multiple myeloma (MM) . Antibodies are used to assess its oncogenic activity in cell proliferation assays .
-
Tissue localization: IHC studies reveal DAZAP1 expression in prostate cancer (PCa) tissues, with suggested antigen retrieval using TE buffer (pH 9.0) .
Tissue Expression and Usage
DAZAP1 exhibits tissue-specific expression patterns, as mapped by the Human Protein Atlas :
| Tissue | Expression Level | DAZAP1 Function |
|---|---|---|
| Testis | High | Spermatogenesis regulation |
| Prostate cancer | Elevated | Oncogenic signaling |
| Pancreatic cancer | Upregulated | Ferroptosis suppression |
Antibodies are commonly used to validate these expression profiles in clinical samples, such as PC tissues (n=10) , and to monitor therapeutic responses in cancer models .
Research Findings and Clinical Relevance
-
Pancreatic cancer: DAZAP1 knockdown induces ferroptosis, inhibiting tumor growth . Antibody-based IHC confirmed DAZAP1 overexpression in PC tissues compared to normal counterparts .
-
Multiple myeloma: DAZAP1 promotes proliferation via ERK signaling modulation, with antibody-validated splicing of KITLG mRNA .
-
Diagnostic potential: High DAZAP1 expression in MM correlates with poor survival (GSE5900, GSE2658) , suggesting its utility as a biomarker.
Product Specs
Target Background
- Research suggests that DAZAP1 suppresses cox6c pre-mRNA splicing. Reduced DAZAP1 expression leads to increased COX6C protein levels, potentially contributing to cell growth retardation. PMID: 29505834
- DAZAP1, as a splicing activator, integrates splicing control into the MEK/Erk pathway, which regulates cell proliferation and migration. PMID: 24452013
- Studies have identified a 42-amino acid segment (N42) at the N-terminus of DAZAP1 that is essential for its transcription-dependent nuclear localization. PMID: 23111326
- Evidence indicates that the splicing factors hnRNPA1/A2, HuR, and DAZAP1, along with the DHX36 RNA helicase, bind to the ISE. While hnRNPA1 has a negative effect, DAZAP1 positively influences splicing selection. PMID: 21858080
- DAZAP1 is capable of regulating mRNA translation. PMID: 21576381
- Research suggests that the interaction between MEF2D and DAZAP1 may contribute to leukemogenesis by altering signaling pathways normally regulated by wild-type MEF2D and DAZAP1. PMID: 15744350
- This study reveals the expression patterns of DAZAP1 in human corpus luteum cells and demonstrates the in vivo interaction of DAZ-like protein (DAZL) with DAZAP1. PMID: 16209998
- DAZ cannot bind simultaneously to DAZAP1 and poly(A)-binding protein (PABP). This suggests that phosphorylation-induced dissociation of DAZ and DAZAP1 may allow DAZ to stimulate translation by interacting with PABP. PMID: 16848763
- The binding of the splicing factors hnRNPA1/A2 and DAZAP1 is the primary determinant of T6 BRCA1 exon 18 exclusion. PMID: 18391021
- Findings suggest that DAZAP1 is a component of complexes involved in the degradation and silencing of mRNA. PMID: 19285026
